Sun Pharma Share Price Target: Pharma giant Sun Pharmaceutical has entered into a definitive agreement to acquire the US-based Organon & Co (Organon) in an all-cash transaction deal.
The deal values Organon at an enterprise valuation of USD 11.75 billion. The transaction is expected to complete in early CY27, according to a report by domestic brokerage firm HDFC Securities.
Under the deal, Sun Pharma's subsidiary will merge with Organon, which will then delist from the NYSE.
While Sun Pharma’s acquisition of Organon will provide scale, growth revival in established brands, cross leverage of Sun Pharma’s branded generic business, and sustaining growth in the Innovative Medicine business with a focus on cross-selling and in-licensing remain key.
After the Organon deal, HDFC Securities has said that it is rolling forward the Sun Pharma share price target to Rs 2,030, with a Buy rating.
Sun Pharma share price closed with a gain of around 7 per cent at Rs 1,731 on Monday (April 27). Sun Pharma share price target implies an upside of 17 per cent from Monday's closing.
